SIRONA/TFChem SGLT differenceAnd here is the difference that Sirona and TFChem have. It has to dowith the chemical composition and how long the SGLT and how well theSGLT works in the body:
TFChem has developed the synthetic technology forthe preparation of glycoconjugate analogues which are stabilized byinnovative fluorinated functional units. This strategy removes atechnological lock by solving the stability issues of carbohydrate-basedmolecules, which is the major limitation to their commercialization. Plus....the France Government support.......
M
“It isoutstanding that in the whole of France our partner, TFChem was selected forunique government funding. It hasresulted in what today is now a truly world class state-of-the-art labfacility.
TFChemheld a grand opening of its new 5,400 square foot lab that has been supportedby French government funding in a PharmaParc close to all the major ‘BigPharma’ companies in Val de Reuil, near Rouen,France.
TFChem’s president, Dr.Géraldine Deliencourt-Godefroy, said“This was the first funding operation of this type in France by thegovernment and TFChem, with two other companies, uniquely, were the firstselected. This is a major step for TFChem’s development. All the team has nowmoved into the new laboratories.”
“This event brought pharmaceutical companies and politiciansto visit and learn more about TFChem’s activities, and the partnership withSirona on the development of new SGLT inhibitors. The first in vitro milestonewe achieved in this program is also great news at this stage. It supports theefficacy of the GlycoMim® technology, and gives us confidence in ourdevelopment plan,” commented Dr. Deliencourt-Godefroy.